Common Contracts
2 similar null contracts by Evaxion Biotech a/S
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.February 2nd, 2021
WHEREAS: 6 ARTICLE 1 7 1.1 INTERPRETATION 7 1.2 DEFINITIONS 7 ARTICLE 2 16 2.1 AMOUNT OF CREDIT 16 2.2 DISBURSEMENT PROCEDURE 16 2.2.1 TRANCHES 16 2.2.2 DISBURSEMENT OFFER 16 2.2.3 DISBURSEMENT ACCEPTANCE 17 2.3 DISBURSEMENT ACCOUNT 17 2.4 CURRENCY OF DISBURSEMENT 17 2.5 CONDITIONS OF DISBURSEMENT 17 2.5.1 INITIAL DOCUMENTARY CONDITIONS PRECEDENT 17 2.5.2 ALL TRANCHES - DOCUMENTARY CONDITIONS PRECEDENT 17 2.5.3 ALL TRANCHES–OTHER CONDITIONS 18 2.5.4 TRANCHE A–ADDITIONAL CONDITIONS PRECEDENT 18 2.5.5 TRANCHE B–ADDITIONAL CONDITIONS PRECEDENT 18 2.5.6 TRANCHE C–ADDITIONAL CONDITIONS PRECEDENT 18 2.6 CANCELLATION 19 2.7 FEE FOR CANCELLATION OF AN ACCEPTED TRANCHE 19 2.8 CANCELLATION AFTER EXPIRY OF THE CREDIT 19 2.9 DROP DEAD FEE 20 2.10 SUMS DUE UNDER ARTICLE 2 20 ARTICLE 3 20 3.1 AMOUNT OF LOAN 20 3.2 CURRENCY OF REPAYMENT, INTEREST AND OTHER CHARGES 20 ARTICLE 4 20 4.1 DEFERRED INTEREST FIXED RATE 20 4.2 VARIABLE REMUNERATION 20 4.3 INTEREST ON OVERDUE SUMS 22 ARTICLE 5 23 5.1 NORMAL R
ContractEvaxion Biotech a/S • January 8th, 2021 • Biological products, (no disgnostic substances)
[****] This symbol identifies certain confidential information contained in this document that has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
